The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Tuesday that its parent company will incur a ~10c annual negative impact on 2023 and 2024 earnings per share as a result of a deal with Cellular Biomedicine Group (CBMG) for CAR T-cell therapies.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.